Eylea Treatment for Wet Macular Degeneration (AMD)
27.11.2012 Eylea in Europa zugelassen
Eylea: grünes Licht für neues Augenmedikament zur Behandlung der feuchten altersbedingten Makuladegeneration (AMD) in der EU
Weiterlesen: Neues Augenmedikament Eylea gegen AMD erhält Zulassung in Europa
Overview Eylea Treatment for Wet Macular Degeneration (AMD)
EYLEA was approved in the United States for the treatment of wet AMD in November 2011 and for macular edema following CRVO in September 2012. EYLEA was also approved in Europe, Japan, Australia, and in several other countries earlier this year for use in wet AMD.
One of Eylea’s key selling points will be its less frequent dosing. Bayer’s drug is given every two months after three initial monthly injections, compared to monthly Lucentis injections.
Regeneron today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD)
Nahrungsergänzungsmittel bei altersbedingter Makuladegeneration
Die Wirksamkeit der Zugabe von Vitaminen und Nahrungsergänzungsmitteln ist derzeit Gegenstand intensiver ärztlicher Forschung. Die Pharmaindustrie bietet inzwischen zahlreiche Präparate an, die aufgrund ihrer speziellen Zusammensetzung bei der Prophylaxe und bei der Behandlung der altersbedingten Makuladegeneration helfen sollen (z.B. Doppelherz system Augen Sehkraft + Schutz).
On 20 September 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eylea, 40 mg/ml, solution for injection intended for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Агентство по контролю за продуктами питания и лекарственными средствами США (FDA) одобрило препарат Eylea (афлиберцепт) для лечения влажной формы возрастной макулярной дегенерации
Regeneron Pharmaceuticals Inc. (REGN) won U.S. approval of Eylea, a treatment for a common cause of blindness that will rival Roche Holding AG (ROG)'s Lucentis.
Regeneron Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for EYLEA™ Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).
The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.
For the anticipated FDA announcement on November 18 regarding new treatment for macular degeneration, the American Health Assistance Foundation has experts available for comment, as well as inspiring stories of persons living with the disease.
The comprehensive year-one findings of the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2 studies will be reported by Ursula Schmidt-Erfurth, MD, of the Medical University of Vienna, Austria. Results of the Controlled Phase 3 Evaluation of Repeated intravitreal administration of VEGF Trap-Eye in Central retinal vein occlusion: Utility and Safety (COPERNICUS) study will be reported by Julia Haller, MD, of the Wills Eye Institute in Philadelphia.
A new drug has been developed as a treatment for macular degeneration. The drug named Eylea will compete directly with Lucentis, the current leading treatment for the eye disease.
read more: Eylea Treatment for Macular Degeneration
The drug, known as Eylea, would compete with Lucentis from Basel, Switzerland-based Roche Holding AG. (ROG) Eylea is injected every eight weeks, half as often as Lucentis
Regeneron Pharmaceuticals, Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA'', also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
A Food and Drug Administration panel voted unanimously Friday to recommend to approve a new Regeneron Pharmaceuticals Inc. eye drug Eylea for the treatment of a condition that can lead to blindness
Regeneron Pharmaceuticals Inc. (REGN: News ), said Friday that a panel of the U.S. Food and Drug Administration has unanimously recommended for approval its eye medication Eylea, indicated in the treatment of Wet AMD - a severe eye disorder that results in loss of vision.
Gefällt Ihnen diese Seite zum Thema "Altersbedingte Makuladegeneration"? Bitte empfehlen Sie diese Informationen zur AMD dann Ihren Freunden und Bekannten: